Clinical MedicineUpdated Aug 20, 2026Version v1
Reviewed milestones, validation shifts, standards, datasets, and debates linked to public evidence.
Evidence from New England Journal of Medicine indicates that Multiple intracranial infusions of IL13Rα2-targeted CAR T cells were administered over 220 days. This is tracked as a clinical because it changes how CAR-T and engineered T cell therapies is understood, validated, or applied. It is supported by 2 papers in the same timeline signal.
Evidence from New England Journal of Medicine indicates that Axi-cel achieved an 82% objective response rate, with a 54% complete response rate. This is tracked as a clinical because it changes how CAR-T and engineered T cell therapies is understood, validated, or applied. It is supported by 2 papers in the same timeline signal.
Evidence from New England Journal of Medicine indicates that CAR therapy aims for durable remissions in treatment-refractory tumors. This is tracked as a clinical because it changes how CAR-T and engineered T cell therapies is understood, validated, or applied. It is supported by 2 papers in the same timeline signal.
Evidence from Frontiers in Immunology indicates that CAR-T and TCR-T cell therapies have shown substantial advances in treating malignant tumors. This is tracked as a clinical because it changes how CAR-T and engineered T cell therapies is understood, validated, or applied. It is supported by 2 papers in the same timeline signal.
Evidence from Journal for ImmunoTherapy of Cancer indicates that TIGIT is upregulated on immune cells and binds to ligands expressed by tumor cells. This is tracked as a clinical because it changes how CAR-T and engineered T cell therapies is understood, validated, or applied. It is supported by 3 papers in the same timeline signal.
Evidence from Blood Cancer Journal indicates that CAR-T cell therapy has shown remarkable responses in certain B cell leukemias/lymphomas. This is tracked as a clinical because it changes how CAR-T and engineered T cell therapies is understood, validated, or applied. It is supported by 2 papers in the same timeline signal.
Evidence from Journal of Clinical Investigation indicates that CAR T cells from naive/stem memory T cells (TN/SCM) show superior antitumor activity and persistence in vivo. This is tracked as a clinical because it changes how CAR-T and engineered T cell therapies is understood, validated, or applied.
Evidence from Science Advances indicates that TCR-T cells offer a broader target repertoire beyond membrane proteins compared to CAR-T cells. This is tracked as a clinical because it changes how CAR-T and engineered T cell therapies is understood, validated, or applied.
Evidence from British Journal of Cancer indicates that Adoptive T-cell therapy can lead to durable responses and cure in some cancer patients. This is tracked as a standard because it changes how CAR-T and engineered T cell therapies is understood, validated, or applied.